Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bates

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Anticancer Research|October 28, 2020
Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma SamplesMartin Filipits, Matthias Preusser, Johannes A Hainfellner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2002
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patientsNancy S Shulman, Michael D Hughes, Mark A Winters, et al.
NPJ Breast Cancer|September 5, 2019
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancerSwati Gupta, Veronique Neumeister, John McGuire, et al.
AIDS (London, England)|March 4, 2006
The independent effect of drug resistance on T cell activation in HIV infectionPeter W Hunt, Steven G Deeks, David R Bangsberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2009
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjectsGail Skowron, John G Spritzler, Jodi Weidler, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 12, 2017
High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescenceBrad E Wasserman, Daniel E Carvajal-Hausdorf, Kenneth Ho, et al.
American Journal of Clinical Pathology|May 29, 2021
Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing CountryMarcellin Mugabe, Kenneth E Ho, Deo Ruhangaza, et al.
BMC Cancer|February 25, 2010
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancerMasakazu Toi, Jeff Sperinde, Weidong Huang, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanomaSwati Gupta, Leena McCann, Yvonne G Y Chan, et al.
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Anticancer Research|October 28, 2020
Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma SamplesMartin Filipits, Matthias Preusser, Johannes A Hainfellner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2002
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patientsNancy S Shulman, Michael D Hughes, Mark A Winters, et al.
NPJ Breast Cancer|September 5, 2019
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancerSwati Gupta, Veronique Neumeister, John McGuire, et al.
AIDS (London, England)|March 4, 2006
The independent effect of drug resistance on T cell activation in HIV infectionPeter W Hunt, Steven G Deeks, David R Bangsberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2009
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjectsGail Skowron, John G Spritzler, Jodi Weidler, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 12, 2017
High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescenceBrad E Wasserman, Daniel E Carvajal-Hausdorf, Kenneth Ho, et al.
American Journal of Clinical Pathology|May 29, 2021
Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing CountryMarcellin Mugabe, Kenneth E Ho, Deo Ruhangaza, et al.
BMC Cancer|February 25, 2010
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancerMasakazu Toi, Jeff Sperinde, Weidong Huang, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanomaSwati Gupta, Leena McCann, Yvonne G Y Chan, et al.
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
Pageof 8